Case report of partial response on second line with Ramucirumab and FOLFIRI in treatment of 74 year old male with metastatic HER2-negative gastric adenocarcinoma
According to the data of the world statistics, gastric cancer (GC) occupies the 5th place by morbidity and the 3rd one by mortality among malignant neoplasms. A significant proportion of patients are elderly patients, the proportion of which in real clinical practice can reach up to 60%. Ramucirumab...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Russo |
| Udgivet: |
Remedium Group LLC
2021-08-01
|
| Serier: | Медицинский совет |
| Fag: | |
| Online adgang: | https://www.med-sovet.pro/jour/article/view/6258 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|